A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm.
| Metric | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | 84M | - | - |
| Net Income | -148M | -126M | -101M |
| EPS | $-3.33 | $-5.13 | $-5.07 |
| Free Cash Flow | -119M | -101M | -84M |
| ROIC | -29.9% | -28.4% | -185.1% |
| Gross Margin | 48.8% | - | - |
| Debt/Equity | 0.15 | 0.22 | -0.22 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -144M | -106M | -85M |
| Operating Margin | -171.5% | - | - |
| ROE | -51.4% | -61.4% | - |
| Shares Outstanding | 58M | 51M | 51M |
| Metric | 2024 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 84M |
| Gross Margin | N/A | N/A | 48.8% |
| R&D | 15M | 16M | 19M |
| SG&A | 70M | 115M | 165M |
| EBIT | -85M | -106M | -144M |
| Op. Margin | N/A | N/A | -171.5% |
| Net Income | -101M | -126M | -148M |
| Net Margin | N/A | N/A | -176.9% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | -185.1% | -28.4% | -29.9% |
| ROE | N/A | -61.4% | -51.4% |
| ROA | -219.5% | -73.8% | -39.0% |
| Cash Flow | |||
| Op. Cash Flow | -72M | -78M | -87M |
| Free Cash Flow | -84M | -101M | -119M |
| Owner Earnings | -85M | -110M | -141M |
| CapEx | 12M | 23M | 33M |
| Maint. CapEx | 12M | 8.0M | 8.2M |
| Growth CapEx | 666K | 15M | 24M |
| D&A | 12M | 8.0M | 8.2M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.5M | 24M | 46M |
| Debt Repayment | 39M | 39M | 39M |
| Balance Sheet | |||
| Net Debt | 29M | -431M | -540M |
| Cash & Equiv. | 8.2M | 238M | 583M |
| Long-Term Debt | 43M | 41M | 42M |
| Debt/Equity | -0.22 | 0.22 | 0.15 |
| Interest Coverage | -13.7 | -13.8 | -13.8 |
| Equity | -209M | 205M | 288M |
| Total Assets | 46M | 296M | 379M |
| Total Liabilities | 465M | 90M | 91M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -406M | -520M | -613M |
| Working Capital | -18M | 217M | 271M |
| Current Assets | 15M | 255M | 314M |
| Current Liabilities | 33M | 38M | 43M |
| Per Share Data | |||
| EPS | -5.07 | -5.13 | -3.33 |
| Owner EPS | -1.66 | -2.14 | -2.41 |
| Book Value | -4.08 | 4.00 | 4.93 |
| Cash Flow/Share | -1.41 | -1.51 | -2.40 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 51.3M | 51.3M | 58.4M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -5.9 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 4.0 |
| Price/Sales | N/A | N/A | 13.8 |
| FCF Yield | N/A | -7.8% | -10.4% |
| Market Cap | N/A | 1.3B | 1.2B |
| Avg. Price | N/A | 23.55 | 19.74 |
| Year-End Price | N/A | 25.12 | 19.74 |
KESTRA MEDICAL TECHNOLOGIES, LTD. passes 0 of 9 quality checks, indicating weak fundamentals.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a 5-year average return on invested capital (ROIC) of -106.8%. This is below average and may indicate limited pricing power.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a market capitalization of $1.2B. It is classified as a small-cap stock.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) does not currently pay a regular dividend.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) generated $-101 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a debt-to-equity ratio of 0.22. This indicates a conservatively financed balance sheet.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported earnings per share (EPS) of $-5.13 in its most recent fiscal year.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a return on equity (ROE) of -61.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a book value per share of $4.00, based on its most recent annual SEC filing.